Omicron News and Research

RSS

Immune particles from llama blood could offer protection against several COVID-19 variants

Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses including SARS-CoV-2 and SARS-CoV-1, which was responsible for the 2003 SARS outbreak.

29 Jun 2022

Study explores antibody responses following three COVID vaccine doses in kidney transplant recipients

In a recent study posted to the medRxiv* pre-print server, Canadian researchers evaluated antibody responses in kidney transplant recipients (KTRs) before and one and three months after receiving the third dose of a messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine.

28 Jun 2022

Study compares protection induced by Delta breakthrough infections vs. COVID boosters against Omicron

Researchers compare the neutralizing ability of antibodies induced by Delta breakthrough infections and a third COVID-19 vaccine against Omicron.

28 Jun 2022

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

In a recent study posted to the bioRxiv* pre-print server, researchers in the United States described a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-neutralizing monoclonal antibody (mAb) SP1-77 that broadly neutralized its multiple variants of concern (VOCs).

28 Jun 2022

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

A study of 10,775 high-risk adult patients during the COVID-19 delta variant surge in late 2021 finds that treatment with one of three anti-spike neutralizing monoclonal antibodies for mild to moderate symptoms led to low rates of severe disease, hospitalization, ICU admission and mortality, according to Mayo Clinic researchers.

28 Jun 2022

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Researchers assessed the in vivo effectiveness of monoclonal antibodies and directly acting antiviral agents against the SARS-CoV-2 Omicron BA.1 and BA.2 sublineages.

28 Jun 2022

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

A recent study by scientists at Celentyx Ltd, the University of Birmingham, and the University of Warwick and posted to the bioRxiv* preprint server illustrated a cell-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein attachment assay.

28 Jun 2022

3rd COVID vaccine significantly reduced hospitalizations and deaths during Australia's 1st Omicron wave

Researchers compare vaccine effectiveness in people who received three doses of the COVID-19 vaccine as compared to those who received two doses.

27 Jun 2022

Infectious period in healthy, vaccinated adults with SARS-CoV-2 is limited, study finds

In January 2022, the U.S. shifted its guidelines to recommend isolation of five days from COVID-19 symptom onset, followed by an additional five days of mask wearing.

27 Jun 2022

Omicron variant of SARS-CoV-2 leads to less severe disease in mouse models

Georgia State University researchers have found that the Alpha, Beta and Delta variants of SARS-CoV-2 were substantially more fatal in mouse models than the original strain of the virus that causes COVID-19.

27 Jun 2022

Researchers investigate clinical epidemiological impact of Omicron among hospitalized COVID-19 patients

Researchers assessed the global impact of the emergence of the SARS-CoV-2 Omicron variant on COVID-19 clinical epidemiology among hospitalized patients.

27 Jun 2022

Breakthrough infection with pre-Omicron variant induces cross-neutralizing activity against Omicron

Researchers evaluated the neutralizing ability of sera from COVID-19 patients.

27 Jun 2022

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Researchers presented the PREVENT-19 phase 3 trial findings on the effectiveness of the NVX-CoV2373 adjuvanted, recombinant S nanoparticle vaccine.

27 Jun 2022

Study investigates the virological attributes of Omicron in a Syrian hamster model

Researchers investigated the virological attributes of SARS‐CoV‐2 new variant of concern Omicron in a Syrian hamster model.

27 Jun 2022

Model-based evidence shows SARS-CoV-2 vaccine boosters should be provided for those eligible ahead of winter

Researchers assessed the SARS-CoV-2 vaccination booster approaches in the face of arising SARS-CoV-2 variants in Europe.

27 Jun 2022

Antigenic differences between early SARS-CoV-2 variants

Researchers used antigenic cartography to quantify and visualize antigenic differences between multiple SARS‐CoV‐2 variants.

27 Jun 2022

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Most research on immunity to the SARS-CoV-2 virus and COVID-19 vaccine development has focused on antibody responses to the spike protein and other viral surface proteins.

24 Jun 2022

Maternal vaccination during pregnancy helps protect babies from being hospitalized due to COVID-19

In a new study sponsored by the Centers for Disease Control and Prevention and published in the New England Journal of Medicine, researchers provide additional evidence that COVID-19 vaccination during pregnancy helps protect babies younger than 6 months from being hospitalized due to COVID-19.

24 Jun 2022

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Scientists have described the development of a modified A549 cell line that shows a robust expression of ACE2 and TMPRSS2 and high susceptibility to SARS-CoV-2 infection.

24 Jun 2022

Serologic testing captures missed children at risk for long Covid

A new study provides evidence of the utility of serologic testing in helping to pick up children with long Covid following missed diagnoses of COVID-19.

24 Jun 2022

Omicron News and Research

Immune particles from llama blood could offer protection against several COVID-19 variants

Study explores antibody responses following three COVID vaccine doses in kidney transplant recipients

Study compares protection induced by Delta breakthrough infections vs. COVID boosters against Omicron

Potent antibody with a novel neutralization mechanism against SARS-CoV-2 variants

Low rates of severe COVID-19 found in patients treated with monoclonal antibodies during delta surge

Effectiveness of monoclonal antibodies and directly acting antivirals against SARS-CoV-2 Omicron BA.1 and BA.2 sublineages

Cell-based assay highlights differences in antibody neutralizing capacity for SARS-CoV-2 variants

3rd COVID vaccine significantly reduced hospitalizations and deaths during Australia's 1st Omicron wave

Infectious period in healthy, vaccinated adults with SARS-CoV-2 is limited, study finds

Omicron variant of SARS-CoV-2 leads to less severe disease in mouse models

Researchers investigate clinical epidemiological impact of Omicron among hospitalized COVID-19 patients

Breakthrough infection with pre-Omicron variant induces cross-neutralizing activity against Omicron

Investigating PREVENT-19 trial findings of serological correlates of immune protection and risk against COVID-19

Study investigates the virological attributes of Omicron in a Syrian hamster model

Model-based evidence shows SARS-CoV-2 vaccine boosters should be provided for those eligible ahead of winter

Antigenic differences between early SARS-CoV-2 variants

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Maternal vaccination during pregnancy helps protect babies from being hospitalized due to COVID-19

Scientists develop suitable human cell line for anti-SARS-CoV-2 drug screening

Serologic testing captures missed children at risk for long Covid

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News